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Abstract
Background: The 46,XY female is characterised by a male karyotype and female phenotype arising due to any
interruption in the sexual development pathways in utero. The cause is usually genetic and various genes are implicated.
Case presentation: Herein we describe a 46,XY woman who was first diagnosed with androgen insensitivity syndrome
(testicular feminisation) at 18 years; however, this was later questioned due to the presence of intact Müllerian structures.
The clinical phenotype suggested several susceptibility genes including SRY, DHH, NR5A1, NR0B1, AR, AMH, and AMHR2. To
study candidate genes simultaneously, we performed whole genome sequencing. This revealed a novel and likely
pathogenic missense variant (p.Arg130Pro, c.389G>C) in SRY, one of the major genes implicated in complete gonadal
dysgenesis, hence securing this condition over androgen insensitivity syndrome as the cause of the patient’s disorder of
sexual development.
Conclusion: This case highlights the emerging clinical utility of whole genome sequencing as a tool in differentiating
disorders of sexual development.
Keywords: Disorders of sexual development, Androgen insensitivity syndrome, Gonadal dysgenesis, Whole genome
sequencing, Next generation sequencing, SRY, Case report
Background
Disorders of sexual development (DSD) are categorised
as 46,XY DSD, 46,XX DSD and chromosomal DSD
(Table 1) with abandonment of pejorative terms such as
intersex and hermaphroditism. DSDs may arise due to
environmental factors such as maternal androgen expos-
ure, or they may arise due to mutations in any of the
genes involved in sexual development in utero. The lead-
ing nosology of the unvirilised 46,XY female are
complete androgen insensitivity syndrome (CAIS) and
complete gonadal dysgenesis (CGD). Whereas CAIS is
due to mutations in the androgen receptor (AR) gene
abolishing the actions of testosterone, CGD may be
caused by various genetic aberrations leading to failure
of testis development and thus testosterone production
and aromatisation of testosterone to oestradiol. In both
CAIS and CGD, effective testosterone deficiency results
in female external genitalia, female body habitus and tall
stature. Primary amenorrhoea is the commonest presen-
tation in both conditions – due to Müllerian regression
in CAIS and due to gonadal insufficiency in CGD [1].
Notably, milder forms of androgen insensitivity syn-
drome (AIS) and mixed or partial gonadal dysgenesis
result in some degree of androgenisation, as do most
androgen biosynthesis defects [1, 2].
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AIS is due to loss-of-function mutations in the AR
gene positioned on the X chromosome and, with an inci-
dence of up to 1/40,000 births, complete AIS (CAIS) is
the commonest cause of the XY female. The molecular
severity of the mutation dictates phenotypic severity,
ranging from mild AIS with male phenotype and
gynecomastia and/or infertility to CAIS with an unam-
biguously female external phenotype [3]. Androgen in-
sensitivity in utero results in variable failure of testicular
descent, which may manifest as bilateral inguinal herniae
or vulval masses. Sertoli cell function is normal in utero
and therefore anti-Müllerian hormone (AMH) produc-
tion typically leads to Müllerian tract regression [1];
however, there are case reports of Müllerian remnants in
CAIS suggesting a hitherto unrecognised role of the an-
drogen receptor in AMH pathways [3]. Breast develop-
ment should occur spontaneously in CAIS due to intact
gonadal androgen production with aromatisation of tes-
tosterone to oestradiol [1].
CGD is characterised by streak gonads due to various
genetic defects specific to testicular development
(Table 1), including deletions and mutations in the sex--
determining region of the Y chromosome (SRY) gene
which account for 15 % of cases [1, 2]. The defect results
in complete failure of testis development and a lack of
gonadal hormone secretion from in utero onwards.
Absence of AMH in utero results in Müllerian tract
persistence and development [4]. Endogenous oestrogen
deficiency prevents spontaneous breast development and
may also cause the unstimulated uterus to be
unidentifiable on imaging. Though androgen production
is impaired in the gonads, it is intact in the adrenals,
resulting in secondary sexual hair. Administration of
oestrogen triggers breast development and uterine
growth whilst cyclical oestrogen/progesterone induces
withdrawal bleeds. CGD should be considered when an
affected woman develops withdrawal vaginal bleeds with
initiation of hormone replacement even if the baseline
imaging failed to demonstrate a uterus; ultrasonography
by radiologists or gynaecologists with special expertise
in the area may be helpful to clarify any inconsistencies
[1].
One of the major utilities of determining an accurate
diagnosis in 46,XY DSD is in guiding gonadectomy since
the risk of gonadal malignancy differs among XY
females. As the tumour risk in CAIS is age-dependent
and only amounts to 16 % over the long term in women
with CAIS and intact gonads, there is an argument to
consider gonadectomy postpubertally after spontaneous
breast development through aromatisation of gonadal
androgens and at an age where girls may be active
participants in their healthcare [5]. In contrast, this is in-
appropriate in CGD where gonadal malignancy rates
approximate 35 % with frequent occurrences in child-
hood [6]. Delay in gonadectomy is also inadvisable in
partial AIS due to the risk of virilisation at puberty as
there is only relative testosterone resistance [1].
The precise cause of 46,XY DSD may also influence
decisions regarding hormone replacement as unopposed
oestrogen therapy in CGD carries risks of endometrial
hyperplasia and carcinoma due to stimulatory effects on
the endometrium [7]. As hormone replacement in CGD
is responsible for breast development and uterine
growth, starting doses should be low and gradually in-
creased to maximise the chances of normal breast con-
tour and full uterine growth [4]. In contrast, oestrogen
monotherapy may be used in CAIS as there is usually an
absence of Müllerian structures, though this should be
reviewed radiologically and at surgery given the afore-
mentioned exceptions [3].
A diagnosis of CGD in 46,XY DSD may offer repro-
ductive opportunities as successful pregnancies using
donated ova have been achieved in women with CGD
[4]. To date, this has not been described in CAIS where
the Müllerian structures are rudimentary. One repro-
ductive opportunity for women with CAIS in the future
is use of their own gametes through in vitro fertilisation
as testes in this condition have been found to contain
spermatogonia, spermatocytes and spermatids [8]. This
remains purely theoretical and ethically questionable
given the risk of CAIS in offspring if gametes carrying
the X chromosome and hence the AR mutation are used.
Nonetheless, women with CAIS cited gamete preserva-
tion as a reason for declining gonadectomy in a survey
Table 1 Overview of DSD categories including example
conditions [1, 2]
DSD category Examples Karyotype or implicated genes
Chromosomal
DSD
Klinefelter’s syndrome 47,XXY and
variants/mosaics




















46,XX DSD Disorders of ovarian
development
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of XY females, therefore this possibility may at least arise
in patient-physician discussions [5].
There may be other clinical differences between CAIS
and CGD which may only be unmasked by studying XY
women with genetically-confirmed diagnoses as ambiguity
in the clinical diagnosis is not uncommon. Of relevance to
our patient who had type 2 diabetes mellitus, endogenous
oestrogen deficiency in childhood and beyond appears to
contribute to glucose intolerance. This might account for
the disproportionately high rates of diabetes mellitus in
gonadal dysgenesis and aromatase deficiency compared to
the background population though how this compares to
women with CAIS remains to be determined [9, 10].
The genetic evaluation of suspected DSD should begin
with a karyotype. Fluorescence in situ hybridisation (FISH)
may be performed simultaneously in the 46,XY female to
confirm an intact SRY gene which is otherwise a straight-
forward cause of CGD. Subsequent investigations have
traditionally involved single or staged gene analysis via
Sanger sequencing guided by the clinical phenotype.
Case presentation
An 18-year-old woman first presented for medical atten-
tion due to primary amenorrhoea. She was then a tall,
thin woman with female external genitalia and no vulval
or inguinal masses, however breast development and
secondary sexual hair were conspicuously absent. The
karyotype was 46,XY leading to a presumptive diagnosis
of CAIS. Because of the suspicion of cryptorchid, dysge-
netic gonads with high malignant potential, the patient
underwent open laparotomy revealing streak gonads
which were removed, and an infantile uterus which was
left in situ. Histopathology demonstrated bilateral gona-
doblastoma, and dysgerminoma in the right gonad. She
received abdominopelvic radiotherapy with no tumour
recurrence. After gonadectomy, she was commenced on
the oral contraceptive pill and later changed to lower
dose hormone replacement therapy.
At age 46 years, the patient migrated to Australia and
sought review at our institution. Her active medical
issues included type 2 diabetes mellitus, dyslipidemia,
obstructive defecation syndrome and colonic polyps. She
had a tall, slim build with a body-mass index of 20.4 kg/m2
and her proportions were eunuchoid with height 181 cm,
arm span 182 cm and lower segment length 102 cm. There
was minimal pubic hair and no axillary hair, but breast
development was now normal. She had female external
genitalia and a retroverted uterus.
Results of hormonal studies and haematocrit were
most consistent with hypogonadal female ranges
(Table 2). Dual-energy x-ray absorptiometry demon-
strated mild osteopenia with T-scores of -1.1 at the hip
and spine. Because of menorrhagia, she underwent
transvaginal ultrasound which demonstrated a fibroid
within an hypoplastic uterus (Fig. 1). No renal tract
anomalies were seen. After failed hysteroscopy and mul-
tiple alterations in hormone replacement, she was
treated with transdermal oestradiol 25 mcg/hr and oral
norethisterone 5 mg daily with cessation of menses at
age 48 years.
It was now, in the patient’s fifth decade of life, that her
original diagnosis of CAIS was questioned. Whilst the
external female phenotype, XY karyotype and absence of
secondary sexual hair were consistent with CAIS, the
presence of streak gonads and functioning Müllerian
structures along with the absence of spontaneous breast
development favoured a diagnosis of CGD. Though
Müllerian remnants have been observed in women
with CAIS, there are no reports of the functioning
uterine structures as found in our patient. We performed
various genetic studies locally, beginning with a digital
karyotype confirming the original 46,XY result. FISH
demonstrated an intact SRY gene, excluding SRY deletion
as the cause of the patient’s atypical DSD. Array compara-
tive genomic hybridisation showed no copy number
variation at an average effective resolution of 0.2 MB.
The major genetic possibilities at this stage were se-
quence variants and copy number variations in known
CGD genes such as DHH, SRY, NR5A1 and NR0B1 [2].
In keeping with the patient’s original diagnosis overseas,
synergistic mutations in AR and AMH or AMHR2 were
considered possible, as this would theoretically result in
an unvirilised XY female phenotype with intact Müllerian
structures. Whole exome sequencing was contemplated as
the next step in our genetic evaluation, however this was
deemed less suitable due to the non-contiguous capture
and amplification steps which may hinder identification of
copy number variations which are a significant cause of
CGD [11]. Single nucleotide polymorphism (SNP) array
was an alternative as its utility has been established in
DSD [12], however the genetic resolution is low and does
Table 2 Results of biochemical tests
Test Unit Result Female reference interval
βHCG U/L <2.0 <15.0a
AFP kU/L 2 <7
Ca-19.9 kU/L 12 <37
AMH pmol/L <3 >14b
FSH IU/L 53 >20a
LH IU/L 24 >10a
Testosterone nmol/L 1.1 <1.5a
SHBG nmol/L 21 20–90a
Free androgen index % 5.0 0.5–5.5a
Packed cell volume L/L 0.39 0.35-0.45
aPostmenopausal range
bPremenopausal range only as postmenopausal status not applicable
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not allow for diagnosis of point mutations [11]. We in-
stead opted for whole genome sequencing (WGS) in order
to examine all susceptibility genes simultaneously and at
high resolution. WGS was also favoured because of its
capacity to detect copy number variations as the entire
genome is contiguously analysed, allowing the detection
of DNA breakpoints in cases of genetic deletions and
duplications [11].
WGS was performed using the Illumina HiSeq X Ten
Sequencing system at the Garvan Institute of Medical Re-
search (Appendix). Bioinformatic analysis was performed
at the SA Pathology Molecular Genetics Laboratory with
variant classification by the American College of Medical
Genetics 5-tier system: benign, likely benign, uncertain
significance, likely pathogenic, or pathogenic [13].
Variants found on WGS were filtered based on muta-
tional consequence (snpEff impact high or moderate)
and phenotypic correlation. WGS revealed variants in
eight genes associated with disorders of sexual develop-
ment, namely: AKR1C4, DMRT1, MAP2K1, MAP3K1,
NR0B1, NR5A1, POR and SRY. All but the NR0B1 and
SRY variants were excluded based on variant population
frequencies >1 % in the 1000 Genomes (1 K), Exome
Sequencing Project (ESP) and Exome Aggregation Con-
sortium (ExAC) databases. The NR0B1 variant was then
excluded because of a population frequency >1 %
amongst individuals in the ExAC database of the same
ethnicity as the patient.
The remaining hemizygous missense variant in the
SRY gene (NM_003140.2, p.Arg130Pro, c.389G > C) was
Fig. 1 Transvaginal ultrasonography demonstrating a hypoplastic uterus with transverse (top) and longitudinal (bottom) sections illustrating the
globular shape. A 4.5 cm fibroid is seen within the uterine cavity, likely contributing to the patient’s menorrhagia
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confirmed to be present on Sanger sequencing of SRY.
This variant has not been previously reported in the 1K,
ESP, ExAC, or dbSNP databases, although there is an
enrichment of pathogenic missense mutations at other
locations of SRY reported in the ClinVar database (Fig. 2).
It is located at the 3’ end of the HMG box domain in a
region required for nuclear localisation (UniProt
Q05066) and it is predicted to be pathogenic by Poly-
Phen2 and MutationTaster, but not SIFT. It is moder-
ately conserved (phyloP 3.43, CADD 10.44) and has a
moderate Grantham difference of 103. Protein-DNA
complex modelling demonstrated that substitution of ar-
ginine (Arg) to proline (Pro) causes steric hindrances to
the native SRY protein structure which may affect DNA
binding (Fig. 3a and b).
The evidence collectively demonstrated this novel SRY
variant to be likely pathogenic, which is consistent with
a diagnosis of 46,XY DSD (OMIM 400044), and more
specifically CGD, thus revising the patient’s diagnosis
from CAIS to CGD 30 years after her original presenta-
tion. The patient’s Müllerian structures were now con-
sidered a consistent feature of her DSD, although the
reason for the absence of secondary sexual hair re-
mains unclear as we excluded a concomitant muta-
tion in the AR gene on WGS.
Conclusions
In the presented case, the patient was phenotypically
female with no evidence of virilisation and we confirmed
a 46,XY karyotype. The leading differentials were
Fig. 2 Domain graph of the novel SRY variant, R130P (underlined), found in the patient alongside pathogenic variants previously reported
in ClinVar
Fig. 3 a Structure of human wild-type SRY protein in complex with the DNA. R130 (pink) is part of the random coil region of wild-type SRY protein.
b The substitution R130P (blue) was shown through homology modelling to create steric hindrances (red dotted lines) to neighbouring residues
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therefore CAIS and CGD. Whilst the absence of second-
ary sexual hair was consistent with CAIS, the presence
of streak gonads and functioning Müllerian structures
along with the absence of spontaneous breast develop-
ment were more suggestive of CGD contrary to her ori-
ginal diagnosis. To overcome the issues of multiple
susceptibility genes and the possibility of either point
mutations or copy number variations, we performed
WGS which identified a novel SRY mutation thus secur-
ing the diagnosis of CGD over CAIS. If we were to have
performed single gene analysis based on the patient’s
original diagnosis, the AR gene would have been se-
quenced with no yield. In current clinical practice, the cost
of WGS is approximately US$2600 with the exact price
depending on laboratory throughput and the technologies
employed. The cost is generally less in research settings
and further decreases are expected with improving effi-
ciency in the sequencing and bioinformatic processes.
With the increasing availability, cost-effectiveness, speed
and understanding of WGS, we support its use in the
clinical evaluation of the XY female due to the presence of
genetic heterogeneity and oftentimes atypical clinical
features in the DSD spectrum.
Appendix
Genetic sequencing methodology
Germline DNA was extracted from blood using a
QiaAMP DNA Mini kit (Qiagen) at SA Pathology,
Adelaide, Australia. WGS was performed by the Garvan
Institute of Medical Research, Sydney, Australia using the
Illumina HiSeq X Ten Sequencing system and paired-end
2x150bp sequencing. A total of 827,574,432 and
835,216,904 reads equating to 62.48 Gb and 63.06 Gb of
raw sequence, respectively, were generated. Bioinformatic
analysis was performed at the SA Pathology Molecular
Genetics Laboratory. Reads were mapped to the human
genome (build hg19) using Burrows-Wheeler Aligner
(BWA) Version 0.7.9a, duplicates marked, indels realigned
and quality scores recalibrated using Picard (V1.71).
Variants were called in exonic regions using the Haploty-
peCaller in the Genome Analysis Toolkit (GATK) Version
3.3.0 following the GATK Best Practice Guidelines. A mean
coverage of 51.89x was achieved in RefSeq exons. Func-
tional annotation was carried out using snpEff and snpSift
(Version 3_3) and Ensembl GRCh37.70 annotation. Vari-
ants were further annotated with information from the
1000 Genomes Project (integrated phase 1 data, Version 3),
Exome Variant Server (ESP6500SI-V2), dbSNP (build 137),
OMIM and GO terms. Variants were filtered based on
minor allele frequency (requiring less than 1 % in the global
individuals from the 1000 Genomes Project) and muta-
tional consequence (snpEff impact high or moderate).
After discarding variants with unrelated phenotype,
eight resulting variants were manually assessed for
disease relationship by examining the OMIM terms and
ExAC allele frequency (http://exac.broadinstitute.org/) and
each was ranked in order of likelihood of being disease-
related. Variant classification by the American College of
Medical Genetics 5-tier system incorporated data from
conservation models (Grantham, CADD, phyloP), in silico
pathogenicity prediction (PolyPhen, SIFT, AlignGVGD,
MutationTaster, Alamut), biophysicochemical properties
(UniProt domain annotations, structural models), published
literature, and mutation databases (ClinVar, HGMD). In
silico mutagenesis of protein-DNA complex (pdb: 1j46.1)
was performed using PyMol and spdbv version 4.10
software.
Validation of the final WGS result was performed via
bidirectional Sanger sequencing of the SRY gene at Flin-
ders Medical Centre, Adelaide, Australia.
Abbreviations
AIS: Androgen insensitivity syndrome; AMH: Anti-Müllerian hormone;
AR: Androgen receptor; CAIS: Complete androgen insensitivity syndrome;
CGD: Complete gonadal dysgenesis; DSD: Disorder of sexual development;
FISH: Fluorescent in situ hybridization; SNP: Single nucleotide polymorphism;
SRY: Sex-determining region of the Y chromosome; WGS: Whole genome
sequencing
Acknowledgements
We would like to thank the patient for participating in this study.
Funding
HSS is supported by a National Health and Medical Research Council
(NHMRC) fellowship (APP1023059). SMCD is supported by an NHMRC clinical
postgraduate scholarship (APP1115188).
Availability of data and materials
The relevant data supporting the conclusions of this article are included
within the article and complete raw data from whole genome sequencing is
available upon request.
Authors’ contributions
SMCD arranged WGS, collated clinical and genetic data and wrote the
manuscript. KSK and LSM performed bioinformatic analysis of the WGS data.
CEC performed protein modelling of the wild-type and mutant SRY products.
HSS supervised all genetic pathology investigations. DJT undertook the clinical
assessment, investigation and management of the patient. KSK, LSM, CEC, HSS
and DJT all edited the manuscript. All authors read and approved the
final manuscript.
Competing interests
The authors declare that they have no competing interests.
Consent for publication
Written informed consent was obtained from the patient for publication of
this case report and any accompanying images. A copy of the written
consent is available for review.
Ethics approval and consent to participate
See below.
Author details
1Endocrine and Metabolic Unit, Royal Adelaide Hospital, Adelaide, SA,
Australia. 2Department of Genetics and Molecular Pathology, Centre for
Cancer Biology, an SA Pathology and UniSA alliance, Adelaide, SA, Australia.
3School of Medicine, University of Adelaide, Adelaide, SA, Australia.
4Hormones and Cancer Group, Garvan Institute of Medical Research, Sydney,
NSW, Australia. 5School of Biological Sciences, University of Adelaide,
Adelaide, SA, Australia. 6ACRF Cancer Genomics Facility, Centre for Cancer
De Sousa et al. BMC Endocrine Disorders  (2016) 16:58 Page 6 of 7
Biology, SA Pathology, Adelaide, SA, Australia. 7School of Pharmacy and
Medical Sciences, University of South Australia, Adelaide, SA, Australia.
Received: 4 May 2016 Accepted: 21 October 2016
References
1. Michala L, Creighton SM. The XY female. Best Pract Res Clin Obstet
Gynaecol. 2010;24(2):139–48.
2. Baxter RM, Vilain E. Translational genetics for diagnosis of human disorders
of sex development. Annu Rev Genomics Hum Genet. 2013;14:371–92.
3. Güven A, Dursun F, Özkanlı S, Güçlüer B, Kuru Lİ. Complete androgen
insensitivity syndrome and discordant Müllerian remnants: two cases with
novel mutation in the androgen receptor. J Pediatr Endocrinol Metab.
2013;26(9-10):909–14.
4. Chen MJ, Yang JH, Mao TL, Ho HN, Yang YS. Successful pregnancy in a
gonadectomized woman with 46, XY gonadal dysgenesis and
gonadoblastoma. Fertil Steril. 2005;84(1):217.
5. Deans R, Creighton SM, Liao LM, Conway GS. Timing of gonadectomy
in adult women with complete androgen insensitivity syndrome (CAIS):
patient preferences and clinical evidence. Clin Endocrinol (Oxf).
2012;76(6):894–8.
6. Cools M, Drop SL, Wolffenbuttel KP, Oosterhuis JW, Looijenga LH. Germ cell
tumors in the intersex gonad: old paths, new directions, moving frontiers.
Endocr Rev. 2006;27(5):468–84.
7. Dewhurst CJ, Koos EB, Haines RM. Replacement hormone therapy in
gonadal dysgenesis. BJOG. 1975;82(5):412–6.
8. Cools M, Van Aerde K, Kersemaekers A-M, Boter M, Drop SL, Wolffenbuttel
KP, et al. Morphological and immunohistochemical differences between
gonadal maturation delay and early germ cell neoplasia in patients with
undervirilization syndromes. J Clin Endocrinol Metab. 2005;90(9):5295–303.
9. Gagliardi L, Scott HS, Feng J, Torpy DJ. A case of Aromatase deficiency due
to a novel CYP19A1 mutation. BMC Endocr Disord. 2014;14(1):16.
10. Rasio E, Antaki A, Campenhout J. Diabetes mellitus in gonadal dysgenesis:
studies of insulin and growth hormone secretion. Eur J Clin Invest.
1976;6(1):59–66.
11. Fromer M, Moran JL, Chambert K, Banks E, Bergen SE, Ruderfer DM, et al.
Discovery and statistical genotyping of copy-number variation from whole-
exome sequencing depth. Am J Hum Genet. 2012;91(4):597–607.
12. White S, Ohnesorg T, Notini A, Roeszler K, Hewitt J, Daggag H, et al. Copy
number variation in patients with disorders of sex development due to 46,
XY gonadal dysgenesis. PLoS One. 2011;6(3), e17793.
13. Richards S, Aziz N, Bale S, Bick D, Das S, Gastier-Foster J, et al. Standards and
guidelines for the interpretation of sequence variants: a joint consensus
recommendation of the American College of Medical Genetics and
Genomics and the Association for Molecular Pathology. Genet Med.
2015;17(5):405–23.
•  We accept pre-submission inquiries 
•  Our selector tool helps you to find the most relevant journal
•  We provide round the clock customer support 
•  Convenient online submission
•  Thorough peer review
•  Inclusion in PubMed and all major indexing services 
•  Maximum visibility for your research
Submit your manuscript at
www.biomedcentral.com/submit
Submit your next manuscript to BioMed Central 
and we will help you at every step:
De Sousa et al. BMC Endocrine Disorders  (2016) 16:58 Page 7 of 7
